Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older
• People who have an advanced solid tumour cancer that has been confirmed by laboratory tissue testing, has continued to grow or spread, and has already been treated with standard cancer treatments (or who could not tolerate those treatments)
• People whose cancer can be measured using standard imaging criteria (called RECIST 1.1)
• People who previously received a type of cancer treatment called a checkpoint inhibitor, where records show the cancer continued to progress during or after that treatment
• People with a general health and activity level rated as 0 or 1 on a standard scale used by doctors (ECOG scale), meaning largely or fully able to carry out daily activities
• People taking part in a specific group within the trial (Part B) who are willing to have a small tumour tissue sample taken before and during treatment, if it is safe to do so
• People who have been free of any other active cancer for at least 2 years
• People whose recent blood and laboratory test results fall within the ranges required by the trial
• People who are willing and able to take part for the full duration of the trial and follow all study procedures, after signing a consent form
• Women who could become pregnant, and men, who agree to use adequate contraception during the trial

Who may not be able to join:

• People with certain blood cancers, specifically acute leukaemia or chronic lymphocytic leukaemia (CLL)
• People with significant heart disease, a heart attack in the past 6 months, or an unstable irregular heartbeat
• People with certain abnormalities in heart electrical activity (including a specific measurement on a heart tracing being too high, a condition called long QT syndrome, or other significant heart tracing abnormalities, including a history of pericarditis)
• People with an active, uncontrolled bacterial, viral, or fungal infection that requires systemic treatment within 7 days before starting the trial
• People with an active autoimmune disease or another medical condition that requires ongoing steroid or immune-suppressing medication
• People with a known HIV, hepatitis B, or hepatitis C infection, unless certain specific conditions are met (confirm with trial site)
• People who have had a major organ transplant or a bone marrow transplant
• People with cancer that has spread to the brain or spinal cord and is causing symptoms
• People with serious non-cancer illnesses
• Women who are pregnant or breastfeeding
• People who have had major surgery within 28 days before the first study dose
• People who have received other anti-cancer treatments within 4 weeks, or within 5 half-lives of that treatment (whichever is the shorter period), before the first study dose — some exceptions may apply (confirm with trial site)
• People with a history of severe allergic reactions to biological therapies, where the trial doctor considers this a safety risk
• People who have had radiation therapy to symptom-causing tumours within 14 days before the first study dose
• People with active substance abuse
• People who have previously had a severe immune-related side effect (Grade 3 or higher) from a prior cancer immunotherapy treatment

Important: Always verify eligibility with the trial site directly before applying.